Sophiris Bio Inc. (SPHS) Rating Reiterated by Roth Capital
Sophiris Bio Inc. (NASDAQ:SPHS)‘s stock had its “buy” rating reissued by equities research analysts at Roth Capital in a report released on Friday. They presently have a $8.00 price objective on the biopharmaceutical company’s stock. Roth Capital’s target price suggests a potential upside of 173.04% from the stock’s previous close.
Several other research analysts also recently issued reports on SPHS. Piper Jaffray Cos. began coverage on shares of Sophiris Bio in a research note on Tuesday, August 30th. They issued an “overweight” rating and a $7.00 target price on the stock. Maxim Group upped their target price on shares of Sophiris Bio from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, August 10th.
Shares of Sophiris Bio (NASDAQ:SPHS) opened at 2.93 on Friday. Sophiris Bio has a 52 week low of $0.80 and a 52 week high of $8.55. The stock’s market cap is $66.27 million. The stock’s 50 day moving average is $2.88 and its 200 day moving average is $2.80.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Sophiris Bio by 90.3% in the second quarter. Vanguard Group Inc. now owns 331,000 shares of the biopharmaceutical company’s stock valued at $712,000 after buying an additional 157,100 shares during the last quarter. Airain ltd boosted its stake in shares of Sophiris Bio by 99.1% in the third quarter. Airain ltd now owns 63,730 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 31,713 shares in the last quarter. KCG Holdings Inc. boosted its stake in shares of Sophiris Bio by 152.3% in the third quarter. KCG Holdings Inc. now owns 42,920 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 25,907 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Sophiris Bio during the third quarter worth approximately $139,000. Finally, Citadel Advisors LLC boosted its stake in shares of Sophiris Bio by 65.2% in the second quarter. Citadel Advisors LLC now owns 49,176 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 19,402 shares in the last quarter. 5.61% of the stock is owned by hedge funds and other institutional investors.
Sophiris Bio Company Profile
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
Receive News & Stock Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related stocks with our FREE daily email newsletter.